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Abstract
The aim of this study was to estimate costs associated with the management of
patients with venous leg ulcers (VLUs) from the perspective of the UK
National Health Service (NHS). The analysis was undertaken through the
Secure Anonymised Information Linkage Databank which brings together and
anonymously links a wide range of person-based data from around 75% of gen-
eral practitioner (GP) practices within Wales (population coverage ~2.5 mil-
lion). The data covered an 11-year period from 2007 to 2017. All patients
linked to the relevant codes were tracked through primary care settings,
recording the number of GP practice visits (number of days with an event
recorded), and wound treatment utilisation (eg, dressings, bandages, etc.)
Resources were valued in monetary terms (£ sterling) and the costs were deter-
mined from national published sources of unit costs. This is the first attempt to
estimate the costs of managing of VLUs using routine data sources. The direct
costs to the Welsh NHS are considerable and represent 1.2% of the annual bud-
get. Nurse visits are the main cost driver with annual estimates of £67.8 mil-
lion. At a UK level, these costs amount to £1.98 billion. Dressings and
compression bandages are also major cost drivers with annual Welsh estimates
of £828 790. The direct cost of managing patients with VLUs is £7706 per
patient per annum, which translates to an annual cost of over £2 billion, when
extrapolated to the UK population. The primary cost driver is the number of
district nurse visits. Initiatives to reduce healing times through improving
accuracy of initial diagnosis, and improved evidence-based treatment pathways
would result in major financial savings.
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1 | INTRODUCTION AND
BACKGROUND
Chronic venous insufficiency is the most common cause
of leg ulceration, in the community.1,2 Major implicating
factors for venous leg ulcers (VLUs) include family history,
obesity, deep venous thrombosis, and increasing age.3 It is
estimated that VLUs affect up to 3% of the adult popula-
tion worldwide4 and are a major cause of morbidity and
decreased health-related quality of life.5 Chronic venous
insufficiency is often not diagnosed until LUs develop, at
which stage its treatment can be difficult and often leads
to patients experiencing a repeated pattern of ulceration,
healing and recurrence. The main stay of treatment for
venous insufficiency includes the use of compression ban-
dages to apply external pressure to the lower limbs with
the aim of improving venous function.6,7 Despite appropri-
ate treatment, the majority of VLUs take several weeks,
even months to heal,3-8 are frequently painful, and
patients can have often high levels of exudate and odour.
This can impact severely on the patients' quality of life and
also lead to other psychological issues such as anxiety,
depression, and social exclusion.9,10 The current health-
related burden of VLUs is imprecise and has been the sub-
ject of several studies that have attempted to estimate, not
only the health impact on the patient, but also the eco-
nomic burden. Guest et al estimated the annual cost of
treating patients with LU in the UK to be £1.94 billion.11
A second study estimated the cost of managing an
unhealed VLU to be four to five times more than that of
managing a healed VLU (£3000 per healed VLU vs
£13,500 per unhealed VLU).12 Finally, the latest study by
Guest et al reported the annual predicted cost of VLU to
be £1.3 billion in the first 12 months from onset.12 The
approach taken by this study differs in the methodology
used by Guest et al.12 The Secure Anonymised Informa-
tion Linkage (SAIL) Databank was interrogated (~2.5 mil-
lion people) over a period of 11 years, whereas the
previous study used a total of 505 patients with VLUs eval-
uated over a 12- month period.
1.1 | Aims and objectives
The aim of this study was therefore to estimate the costs
associated with the management of patients with VLUs
from the perspective of the UK National Health Service
(NHS) using routine data as provided in the SAIL data-
base.Specific objectives of the study were to:
• Establish a profile of patients with VLUs, based on
clinical coding.
• Interrogate routine data to catalogue health services
resource utilisation by this cohort of patients.
• Identify various wound treatments used and their
impact on resource utilisation.
• Estimate the overall costs of managing patients
with VLUs.
• Identify the major cost drivers in the management of
patients with VLUs.
1.2 | Methods
The analysis was undertaken through the SAIL
Databank,13 which brings together, and anonymously
links, a wide range of person-based data from around
75% of general practitioner (GP) practices within Wales
(population coverage ~2.5 million people).14,15 It includes
GP records, outpatient (OP) clinical data, inpatient
Key Messages
• the current health-related burden of venous leg
ulcers (VLUs) is imprecise and has been the
subject of several studies that have attempted
to estimate, not only the health impact on the
patient, but also the economic burden. Annual
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ing accuracy of initial diagnosis, and improved
evidence-based treatment pathways would result
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(IP) episodes, and accident and emergency (A&E)
Department data, to create an encrypted anonymised
linking field for each individual. This linkage allows the
patient pathway to be tracked through the NHS Wales
system both retrospectively and prospectively from a spe-
cific reference point. The patient cohort was identified
through relevant clinical codes, and the resource implica-
tions of their management were collected and estimated
using published sources.16,17
This approach provided an in-depth inventory of the
contacts, consultations, and resources utilised in the current
management of such patients, enabling the potential impli-
cations of adjustments to these management approaches.
1.3 | Data analysis
The SAIL database was interrogated to catalogue health
service resource utilisation by this cohort of patients. We
used the GP Data to identify and quantify all events in
order to measure service usage.
The Welsh Demographic Service Data18 was utilised
to gather basic demographics, information on follow-up
time (residency in Wales and GP registrations), and
Welsh Index of Multiple Deprivation19 score to measure
deprivation.
1.4 | Resource use
All patients linked to the relevant codes were tracked
through primary care settings, recording their level of GP
practice visits (number of days with an event recorded)
and wound treatment utilisation (eg, dressings, bandages,
etc.). District nurse visits were not available in the data,
so the extent of district nurse time involved in the man-
agement of the VLU wounds was estimated as two visits
per week. This estimate was based on detailed discus-
sions with several clinicians and a tissue viability nurse.
1.5 | Cost data
Resources were valued in monetary terms (£ sterling) and
the costs determined from national published sources of
unit costs including the British National Formulary (BNF)16
and Personal and Social Services Research Unit (PSSRU)
unit costs,17 where costs were unavailable and/or local costs
were utilised (eg, from local financial records or NHS Wales
formulary); these were provided by other sources. The cur-
rency year was 2018, while an inflation calculator (Bank of
England) was used to convert previous years' costs to cur-
rent prices (Table 1).
1.6 | Perspective
The perspective taken was that of the UK NHS.
1.7 | Statistical analysis
Statistical analysis was undertaken in SPSS Version
25 for Windows. Furthermore, basic descriptive demo-
graphic statistics were also collected alongside the
resource use and cost data. Survival analysis of treatment
duration was conducted using R 3.5.
2 | RESULTS
The report utilised primary care data from the SAIL
Databank, covering approximately 75% of GP practices in
Wales. The study period was between 2007 and 2017.
A VLU was defined as either a specific code that
implies a VLU, or the combination of a non-specific ulcer
code with a code for either compression stockings or vari-
cose veins. Non-specific codes included codes such as
“recurrent LU” (M274.), “non-healing LU” (M273.), and
“traumatic LU” (M2716), where a combination of codes
was used:
• For the combination of ulcer code and varicose veins,
there was no time restriction: each code could appear
anywhere within the study period.
TABLE 1 Unit costs used in the analysis
Health service
resource
Unit
cost (£) Source
GP surgery visit (per
surgery consultation
lasting 9.22 min)
£38 PSSRU 2018
GP home visit £120 PSSRU 2013 (inflated to
2018 prices using BOE
calculator)
Practice nurse £42 PSSRU 2018
GP telephone triage £14.80 PSSRU 2018
Practice nurse
telephone triage
£7.70 PSSRU 2018
District nurse £78 PSSRU 2015 (inflated to
2018 prices using BOE
calculator)
Dressings, bandages, medication, etc.
Various £ BNF (2018)
Abbreviations: BNF, British National Formulary; BOE, Bank of
England; PSSRU, Personal and Social Services Research Unit.
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• For the combination of an ulcer code and a stocking,
the ulcer diagnosis code was required to come first.
The date of diagnosis with VLU was the first occurrence
of a VLU code (either specific or non-specific) (Table 2).
2.1 | Cohort demographics
Of the cohort of 8352, 56% (n = 4,648) were female and
44% male (n = 3,704). The average age of females was
74.8 and 68.4 years for males.
2.2 | Treatment
Read codes in the GP data only show the occurrence of a
prescription. They do not show the quantity or dose, so
the counts shown represent number of prescriptions
(each of which may be for multiple items).
The cost of all the treatments (dressings, bandages,
compression stockings, etc.) over the 11 years linked to
the VLU-related codes (n = 8352) was costed (taking into
account multiple items) using the BNF and GP Prescrip-
tion data from Primary Services Wales,20 where the aver-
age number of items per prescription per patient was
estimated (Table 3).
Table 4 summarises the costs of all the treatment
types. The main cost drivers were “Compression Other”
(£1,754,951) and “Dressing” (£6,157,949).
2.3 | Cost of GP event days
Not all days with an event represent consultations with
a GP. Some are prescription renewals, receipt of letters
from hospital, and other activities. There is no reliable
way from the data held in SAIL to identify the number
of patient consultations. The assumption was made
that 33% of all days with an event recorded represented
a consultation. This estimate was based on discussions
with several clinicians and a GP. This is probably a
conservative assumption, because it results in consulta-
tion rates per person-year that are lower than previ-
ously published rates for the UK21 while the cohort in
this study is older and is known to have health issues
requiring a high level of care. Therefore, a pragmatic
approach to defining and costing a GP contact was
TABLE 2 Cohort characteristics
Read code n
A specific venous leg ulcer (VLU) code (M2714 and
M2715)
1828
A non-specific VLU code combined with compression
stocking
3104
A non-specific VLU code combined with varicose veins 3420
Total 8352
TABLE 3 Events by treatment type (2007-2017)
Treatment Patients Event/prescription count Avg. per patient Sum (£)
Hydrocellular foam 107 277 2.6 £19 932
Hydrofiber Ribbon 365 1269 3.5 £25 856
Barrier Cream 874 4393 5.0 £15 100
Barrier Spray 540 1824 3.4 £17 071
Compression Applicator 1047 1267 1.2 £35 355
Compression Other 3906 61 693 15.8 £1 754 951
Compression Stocking 3607 14 741 4.1 £585 803
Autolytic hydrogels 1104 3782 3.4 £134 663
Autolytic Manuka Honey 1107 3037 2.7 £64 606
Dressing 7002 193 161 27.6 £6 157 950
Gauze 1306 7306 5.6 £27 320
Line 2827 23 211 8.2 £83 757
Swab 180 573 3.2 £21 645
Swab 363 1909 5.3 £9306
Elasticated tubular support bandage 1457 9414 6.5 £17 851
Total 25 792 327 857 12.7 £8 971 166
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taken, assuming that 82% of consultations were con-
ducted at the surgery, 12% of consultations were
over the telephone, and 3% were either home visits or
conducted at other locations.22 For ease of analysis and
to combat the unknown quantity of “other locations,”
the 3% conducted at other locations were added into
the telephone consultations to make them 15% of
the 82%.
Additionally, the study disaggregated the numbers
further, by assuming that 62% of the above-mentioned
consultations were undertaken by GPs. Thirty-four per-
centage were undertaken by practice nurses and 4% by
other clinicians. Again, for ease of analysis and the
unknown quantity of “other clinicians,” the 4% other cli-
nicians were classed as being undertaken by practice
nurses (Table 5).
TABLE 4 Summary of all
treatment types by group (2007-2017)
Group N Mean (SD) Sum
Hydrocellular foam 7 £2847 (£5002) £19 932
Hydrofiber Ribbon 4 £6464 (£6309) £25 856
Barrier Cream 9 £1678 (£3329) £15 100
Barrier Spray 2 £8536 (£11 646) £17 072
Compression Applicator 3 £11 785 (£16 616) £35 355
Compression Other 116 £15 129 (£94 110) £1 754 951
Compression Stocking 93 £6299 (£23 228) £585 803
Autolytic Hydrogels 21 £6413 (£16 106) £134 663
Autolytic Manuka Honey 30 £2154 (£4982) £64 606
Mechanical Debridement 2 £48 708 (£68 031) £97 415
Passive Debridement 7 £5923 (£12 085) £41 461
Sharp Debridement 11 £604 (£925) £6647
Dressing 912 £6752 (£33 333) £6 157 949
Gauze 5 £5464 (£5649) £27 320
Line 54 £1551 (£4321) £83 757
Swab type one 2 £10 823 (£10 448) £21 645
Swab type two 2 £4653 (£1700) £9306
Elasticated tubular support bandage 12 £1488 (£2436) £17 850
Total 1292 £6136 (£23 350) £9 116 690
TABLE 5 Estimated consultations and costs by year
Year
Days with an
event
Estimated
consultations
Patient
count
Avg. per
patient GP cost
Nurse
cost
Total
cost
2007 12 357 4119 1021 4.0 £94 439 £59 705 £154 144
2008 23 572 7857 1709 4.6 £180 150 £113 893 £294 043
2009 29 279 9760 2204 4.4 £223 766 £141 467 £365 233
2010 34 716 11 572 2506 4.6 £265 318 £167 737 £433 055
2011 38 903 12 968 2760 4.7 £297 317 £187 968 £485 285
2012 37 227 12 409 2929 4.2 £284 509 £179 870 £464 378
2013 38 201 12 734 3173 4.0 £291 952 £184 576 £476 528
2014 40 952 13 651 3283 4.2 £312 977 £197 868 £510 845
2015 40 047 13 349 3405 3.9 £306 061 £193 495 £499 556
2016 34 783 11 594 3326 3.5 £265 830 £168 061 £433 891
2017 28 207 9402 3186 3.0 £215 573 £136 288 £351 861
Total 358 244 119 415 29 502 4.0 £2 737 892 £1 730 928 £4 468 819
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The unit costs for health care utilisation were
obtained from a number of PSSRU sources17,23 and are
shown in Table 1.
2.4 | Total resource utilisation
Table 6 summarises all the costs relating to VLU treat-
ment observed via the GP data within the SAIL Databank
over the 11 years. Furthermore, the “observed” data has
been extrapolated to all-Wales and UK populations. This
results in an estimated annual cost of treating VLUs of
£68,986,470 for the “observed” data or £8,260 per patient
annually for the cohort based on UK prevalence.
When resource use is compared with prescription
use, there were 2.7 times as many prescriptions as
there were estimated consultations—that is,
321,038/119,415. The cost of prescribed treatments was
roughly twice the cost of consultations—that is,
£9,116,690/£4,468,819.
3 | DISCUSSION
This is the first to attempt to estimate the economic bur-
den of VLUs using the SAIL Databank. The direct costs to
the Welsh NHS are considerable and represent 1.2% of the
annual budget. District Nurse visits are the main cost
driver, with annual estimates of £67,751,424. At a UK
level, these costs amount to £1,987,375,104.Dressings and
compression bandages are also significant cost drivers with
annual Welsh estimates of £8,771,897. In terms of the
SAIL estimates, this represents 12.6% of the total treatment
budget. An earlier study using the SAIL data base showed
that 3% of spend for all wounds in primary care was
directed at the costs of dressings.24 This difference could
be due to the increase in SAIL Databank coverage since
the publication of that study (45% Vs 75%), and also the
use in this study of a more sophisticated and sensitive link-
age algorithm. When resource use is compared with pre-
scription use, the percentage use of prescriptions per
resource used (ie, GP or nurse consultation) is 2.7 prescrip-
tions per patient—that is, 321,038/119,415. When the costs
are compared, the average prescription cost is £2 per
patient—that is, £9,116,690/£4,468,819.
The estimates presented in this study are generally
comparable to Guest et al's 2017 paper11 where annual
English NHS costs are estimated to be £1.3 billion.
The results confirm other findings associated with the cost
of wound care. It is mistakenly believed that the use of wound
management materials per se is the major cost driver in treat-
ment costs, whereas in reality, nursing time and hospital costs
are together responsible for the around 80% and 85% of the
total cost.25 Healing times, frequency of dressing changes, and
complications are three important drivers of cost.
Previous authors have also demonstrated that the
management and treatment of chronic venous ulcers add
substantial costs to global health care systems, as well as
having a negative impact on patient's quality of life.12
The results of this study have also demonstrated that
treating VLUs consumes large amounts of medical prod-
ucts, drugs, and compression bandaging. In terms of
health care clinical practitioners treating this condition,
the application of compression bandaging, an essential
component of treatment, is known to be variable.26 Fur-
thermore, the plethora of available wound dressings, with
varying evidence relating to their effectiveness, also pose
challenges in developing individual care pathways.
There is increasing evidence that there is significant
sub-optimal service delivery in relation to wound man-
agement, and which is not based on notions of best prac-
tice. These include inadequate diagnosis, failure to
identify the wound type, not using best practice for man-
aging the underlying pathology, and the lack of adequate
health professional education and training.27
TABLE 6 Summary table of all treatment and visit costs
Overall summary of VLU-related treatment and resource
use costs
SAIL observed
8352 No. of patients
£4 468 819 GP events/contacts
£9,116 689 Treatments
£745 265 664 DN visits (based on 2 per week)
£758 851 172 Total over 11 years
£68 986 470 Estimated annual cost of treatment
(n = 8352)
Wales
11 136 No. of patients
£5 586 024 GP events/contacts
£11 395 861 Treatments
£993 687 552 DN visits (based on 2 per week)
£1 010 669 437 Total over 11 years
£91 879 040 Estimated annual cost of treatment
(n = 11 136)
UK
244 992 No. of patients
£10 892 747 GP events/contacts
£16 412 092 Treatments
£21 861 126 144 DN visits (based on 2 per week)
£21 888 430 983 Total over 11 years
£1 989 857 362 Estimated annual cost of treatment
(n = 244 992)
Abbreviations: DN, district nurse; GP, general practitioner; SAIL,
Secure Anonymised Information Linkage.
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Possibly, the best way of attacking these particular
challenges is looking at reducing waste, harm, and varia-
tion in practice and ensuring that there are local,
regional, national, and international guidelines, proto-
cols, algorithms, and care pathways that should be
followed, wherever possible, for the vast majority of
patients. In addition, the continued creation of local,
regional, and national centres of excellence, where
patients with complex LUs could be assessed and their
wounds resolved would be of great benefit.
Innovative medical approaches are evolving that will
provide additional alternatives and additions to current
practices to heal VLUs faster, and have the potential to
significantly reduce the total cost of treatment of such
wounds. Two illustrative examples will be discussed.
Although compression therapy improves venous ulcer
healing, it does not treat the underlying causes of
venous hypertension. Treatment of superficial venous
reflux has been shown to reduce the rate of ulcer recur-
rence, but the effect of early endovenous ablation of
superficial venous reflux on ulcer healing remains
unclear. In a large randomised study, 450 patients
undergoing early endovenous ablation of superficial
venous reflux with compression resulted in faster
healing of venous ulcers and more time free from ulcers
than ulcers treated with compression and deferred
venous ablation.28 A second example of innovation that
could potentially help to speed up ulcer healing is the
use of topical multimodal anaesthesia combined with
adrenaline and an antimicrobial prior to and post-
wound debridement. Ensuring confidence in the attend-
ing clinician to debride and giving the patient a pain-
free experience while optimising wound bed preparation
will lead to successful outcomes. If wound bed prepara-
tion is optimised early in the treatment pathway faster
healing may occur. The potential clinical and economic
benefits of topical multi- modal anaesthesia as part of
achieving pain relief during debridement have been
summarised in a recent publication.29 It is rec-
ommended that better education of debridement types
in the curriculum for nurses at University undergradu-
ate level would also help tackle the issue of choosing
the appropriate debridement techniques in practice. This
would also help address the issue of whether the right
professionals are debriding at the right time, in the right
manner, and in the right context.
3.1 | Strengths and limitations
SAIL data base that covers nearly 70% to 80% of welsh
population was used and extrapolations made from this
represent a more realistic estimate of the problem.
Although clinical coding may be an issue, we have
tried to improve the quality of data using the more accu-
rate prescription data to qualify the picked up clinical
codes.
The results of the study provide an important refer-
ence point for policy makers in concerting resources and
strategies in tackling the main cost drivers for this condi-
tion. While it is the ideal in aiming complete healing of
ulcers, this is not always possible. To improve resource
efficiency, strategies/treatments that effectively reduce
clinician/district visits should be used.
Secondary care data have not been included due to
the difficulty in identifying what care is driven by VLUs.
The national out-patient data in Wales do not contain
information on diagnoses and treatments. Further
research is needed to investigate the coding structure of
these events within SAIL and how best to tackle the
issues without having to make too many assumptions.
Inpatient stays are also missing from this analysis due to
a similar coding problem. However, as the treatment of
VLUs is likely to take place in primary community care
by practice nurses and district nurses, the assumption
was made that there would be an insignificant level of
VLU-related inpatient activity.
The coding issues relating to GP events/contacts are
another limitation which were addressed in the assump-
tions made. However, by using the existing evidence laid
out by Hippisley-Cox (2009),22 a reasonable assumption
was made of the types of contact that patients would have
with either the GP or the practice nurse.
The estimate of two district nurse visits per week
may be an underestimate of the actual “real-world” fre-
quency of visits by these practitioners to change dress-
ings, bandages, etc. If the average number of district
nurse visits were increased to three, then the observed
SAIL estimate of annual costs would be £102,862,182 or
£12,316 per patient. Being able to accurately identify
district nurse visits within the SAIL databank would be
advantageous for future wound-related routine data
research.
We recognise that the relatively narrow perspec-
tive of the Welsh NHS is a limitation. However, we
believe it still to be reflective of the UK NHS as a
whole.
Additionally, we have not costed other health-related
costs, such as the use of other medications such as pain
killers, antibiotics, etc.
Finally, the relatively narrow perspective of Welsh
NHS costs shows just one picture of the economic burden
VLUs have on the UK health care system. A wider, more
societal perspective would shed light on further substan-
tial costs relating to caregivers, loss of productivity, and
health-related quality of life.
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4 | CONCLUSION
The direct Welsh NHS costs of relating to the managing
patients with treatment of VLUs is £7,706 per patient per
annum, which translates to an annual cost of over £2 bil-
lion, when extrapolated to the UK population. The pri-
mary cost driver is the number of district nurse visits.
Future initiatives to reduce healing times, through
improving accuracy of initial diagnosis, and improved
evidence-based treatment pathways would result in
major financial savings.
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